



**Aspira Pathlab & Diagnostics Limited**  
**Registered. Office:** Flat No. 2, R D Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai-400086  
**Corporate Office:** 6 & 7, Bhaveshwar Arcade, Near Shreyas Junction LBS Marg, Behind Saraswat Bank, Ghatkopar (W), Mumbai-400086  
**CIN:** L85100MH1973PLC289209

**Date: February 10, 2026**

To,  
Listing Department  
**BSE Limited,**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai-400001.

**Security Code: 540788**

**Security ID: ASPIRA**

**Sub: Outcome of Board Meeting held on Tuesday, February 10, 2026**

Dear Sir/Madam,

In compliance with the SEBI (LODR) Regulations, 2015 ("Listing Regulations") this is to inform you that the Board of Directors of the Company, at its Meeting held today, i.e. on Tuesday, February 10, 2026 inter alia, has considered, approved and taken on record the following matter(s):

1. Un-Audited Standalone Financial Results along with Limited Review Report for the third quarter/nine months ended December 31, 2025 ("the financial results") duly reviewed and approved by the Audit Committee and Board of Directors as per regulation 33 of the Listing Regulations is attached herewith and
2. Approval for entering into material related party transaction between the Company & M/s. Yashraj Research Foundation for sale of services of INR 5 crores subject to member's approval.

Kindly note that Board Meeting commenced at 05.15 P.M (IST) and concluded at 6.34 P.M.(IST)

The above information is being made available on the website of the Company [www.aspiradiagnostics.com](http://www.aspiradiagnostics.com).

We request you to kindly take the same on your record.

Thanking you.

Yours Faithfully,

**For and on behalf of**  
**Aspira Pathlab & Diagnostics Limited**

**Nikunj Mange**  
**Executive Director**  
**DIN: 08489442**

**CERTIFIED TRUE COPY OF THE RESOLUTION PASSED BY THE BOARD OF DIRECTORS OF ASPIRA PATHLAB & DIAGNOSTICS LIMITED ("THE COMPANY") IN ITS MEETING HELD ON TUESDAY, FEBRUARY 10, 2026 COMMENCED AT 06.34 P.M (IST) AT UNIT 6 & 7, GROUND FLOOR, BHAVESHWAR ARCADE PREMISES CO-OP. SOCIETY LTD, NITYANAND NAGAR, GHATKOPAR WEST, MUMBAI-400086, MAHARASHTRA**

**AUTHORISATION FOR SIGNING OF THE UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE THIRD QUARTER/NINE MONTHS ENDED DECEMBER 31, 2025**

**"RESOLVED THAT** pursuant to regulation 33(2)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the unaudited standalone financial results for the third quarter/nine months ended December 31, 2025 be and is hereby approved.

**RESOLVED FURTHER THAT** pursuant to regulation 33(2)(b) of the SEBI (LODR) Regulations, 2015, Mr. Nikunj Mange, Executive Director (DIN: 08489442) of the Company be and is hereby authorised on behalf of the Board members to sign the aforesaid unaudited standalone financial results for the third quarter/nine months ended December 31, 2025".

**For and on behalf of**  
**Aspira Pathlab & Diagnostics Limited**

**Nikunj Mange**  
**Executive Director**  
**DIN: 08489442**



# Sarda Soni Associates LLP

CHARTERED ACCOUNTANTS

**Manoj Jain**

B.Com(H), FCA, ACS, IP(ICAI), RV(S&FA)

**Limited Review Report on unaudited standalone financial results of Aspira Pathlab and Diagnostics Limited for the quarter ended 31 December 2025 and year to date results for the period from 01 April 2025 to 31 December 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.**

**To the Board of Directors of Aspira Pathlab & Diagnostics Limited**

We have reviewed the accompanying statement of **Unaudited Standalone Financial Results of Aspira Pathlab & Diagnostics Limited** (hereinafter referred to as "the Company") for the quarter ended 31 December 2025 and year to date results for the period from 01 April 2025 to 31 December 2025 (the Statement'), being submitted by the company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

This Statement, which is the responsibility of the company's management and approved by the company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of the company's personnel and analytical procedures applied to financial data and thus provide less assurance than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.


Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the accounting principles laid down in Ind AS 34 prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI LODR Regulations 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



For **SARDA SONI ASSOCIATES LLP**

Chartered Accountants

Firm Reg. No. 117235W

  
(MANOJ KUMAR JAIN)

Partner

Membership No.- 120788

UDIN : 26120788BADUMV4219

Place- Mumbai

Date- 10.02.2026

11, Friend's Union Premises Co-operative Society Ltd., 2nd Floor, 227, P. D'Mello Road, Mumbai 400 001.

Phone: 022-2269 5289 ; Mobile: 98191 65816

Email: ssaaudit2102@gmail.com / sardasoniassociates2102@gmail.com

**Nagpur (HO):** "Chartered Square", Samrat Ashok Square, Saraipeth, Nagpur 400 009.

Phone: 0712-2726795, 2729471



**ASPIRA PATHLAB & DIAGNOSTICS LIMITED**

(CIN L85100MH1973PLC289209)

Reg. Office : Flat No. 2, R.D. Shah Bldg., Shradhdhanand Road, Opp. Railway Station, Ghatkopar ( W), Mumbai -400086

Tel No. 022-71975756, Email :support@aspiradiagnostics.com, Website: www.aspiradiagnostics.com

**Statement of Financial Results for the Quarter and Nine months ended 31st December, 2025**

(Rupees in Lakhs except as stated)

Particulars	Quarter ended			Nine Months ended		Year ended
	31-Dec-25 (Unaudited)	30-Sep-25 (Unaudited)	31-Dec-24 (Unaudited)	31-Dec-25 (Unaudited)	31-Dec-24 (Unaudited)	31-Mar-25 (Audited)
<b>1. Income</b>						
(a) Revenue from Operations						
Sales/Income from Operations	511.88	809.28	540.74	1,845.96	1,622.23	2,199.90
(b) Other Income	12.94	13.96	8.86	37.67	25.61	38.89
<b>Total income</b>	<b>524.83</b>	<b>823.23</b>	<b>549.61</b>	<b>1,883.63</b>	<b>1,647.85</b>	<b>2,238.79</b>
<b>2. Expenses</b>						
(a) Cost of Materials consumed	112.19	128.27	84.89	330.05	282.63	369.58
(b) Laboratory Testing Charges	34.86	33.53	22.41	95.81	74.56	99.65
(c) Employee benefits expense	245.07	214.63	196.57	648.71	538.21	732.62
(d) Finance Costs	9.81	9.76	9.41	28.97	25.42	34.74
(e) Depreciation and amortisation expense	38.23	39.55	38.59	114.30	112.64	149.38
(f) Other expenses	240.79	213.94	160.07	591.74	479.36	645.57
<b>Total Expenses</b>	<b>680.95</b>	<b>639.69</b>	<b>511.94</b>	<b>1,809.59</b>	<b>1,512.82</b>	<b>2,031.53</b>
<b>3. Profit / (Loss) before exceptional items and tax (1-2)</b>	<b>(156.12)</b>	<b>183.54</b>	<b>37.66</b>	<b>74.03</b>	<b>135.02</b>	<b>207.26</b>
4. Exceptional Items	-	-	-	-	-	-
<b>5. Profit / (Loss) before tax (3+4)</b>	<b>(156.12)</b>	<b>183.54</b>	<b>37.66</b>	<b>74.03</b>	<b>135.02</b>	<b>207.26</b>
6. Tax Expenses	-	-	-	-	-	-
<b>7. Profit / (Loss) after tax (5-6)</b>	<b>(156.12)</b>	<b>183.54</b>	<b>37.66</b>	<b>74.03</b>	<b>135.02</b>	<b>207.26</b>
8. Other Comprehensive income (net of tax)	-	-	-	-	-	0.04
<b>9. Total Comprehensive income (7+8)</b>	<b>(156.12)</b>	<b>183.54</b>	<b>37.66</b>	<b>74.03</b>	<b>135.02</b>	<b>207.30</b>
10. Paid up Equity share capital (face value of Rs.10 each)	1,029.30	1,029.30	1,029.30	1,029.30	1,029.30	1,029.30
11. Other Equity	-	-	-	-	-	192.34
<b>12. Earning per share (in Rupees)</b>						
(a) Basic	(1.52)	1.78	0.37	0.72	1.31	2.01
(b) Diluted	(1.52)	1.78	0.37	0.72	1.31	2.01

**Notes:**

- The above financial results of the Company for the quarter and nine months ended December 31, 2025 have been reviewed and recommended by the Audit Committee and thereafter approved by the Board of Directors at its meeting held on 10th February, 2026.
- The financial results for the quarter and nine month ended December 31, 2025 has been subjected to limited review by statutory auditors of the Company as required under regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and not subjected to audit. The auditors have expressed an unmodified opinion in the limited review report for the quarter and nine months ended December 31, 2025.
- These financial results of the Company have been prepared in accordance with Indian Accounting standards (Ind AS) prescribed under Section 133 of the Companies Act 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India, to the extent applicable.
- The Board of Directors of the Company, which has been identified as being the chief operating decision maker, evaluates the Company's performance allocates resources based on the analysis of the various performance indicators of the Company as a single unit. Therefore, there is no reportable segment of the Company in accordance with requirement of Ind AS 108 - Operating Segment, notified under the Companies (Indian Accounting Standard) Rules, 2015.
- On 21 November 2025, the Government of India notified the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020. The Company has assessed internally the financial implications of these changes which has resulted in increase in Gratuity Liability of Rs. 12 Lakhs arising out of past service cost which is disclosed under Employee Benefits Expenses. The Company continues to monitor the Central/State Rules and clarifications from the Government on other aspects of the Labour Code and would appropriate accounting effect on the basis of such development, if any, by March 31, 2026.
- Disclosure of segment wise information is not applicable, as pathology services is the Company's only business segment.
- The previous period figures have been regrouped/rearrange/reclassified wherever necessary.

**FOR ASPIRA PATHLAB & DIAGNOSTICS LIMITED**

NKunj Munge  
Executive Director  
DIN. 08489442  
Place : Mumbai  
Date : 10.02.2026


**FOR SARDA SONI ASSOCIATES LLP  
CHARTERED ACCOUNTANTS**

(MANOJ KUMAR JAIN)  
PARTNER  
M No 120700